[1] GRACE R F,BARCELLINI W.Management of pyruvate kinase deficiency in children and adults[J]. Blood,2020,136(11):1241-1249. [2] BIANCHI P L,FERMO E,GLADER B,et al.Addressing the diagnostic gaps in pyruvate kinase deficiency:consensus recommendations on the diagnosis of pyruvate kinase deficiency[J]. Am J Hematol,2019,94(1):149-161. [3] BIANCHI P L,FERMO E.Molecular heterogeneity of pyruvate kinase deficiency[J]. Haematologica,2020,105(9):2218-2228. [4] VALENTINE W N,TANAKA K R,MIWA S.A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital non-spherocytic hemolytic Anemia[J]. Trans Assoc Am Physicians,1961,74:100-110. [5] BEUTLER E,GELBART T.Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population[J]. Blood,2000,95(11):3585-3588. [6] JOHNSON S,GRACE R F,DESPOTOVIC J M.Diagnosis,monitoring,and management of pyruvate kinase deficiency in children[J]. Pediatr Blood Cancer,2022,69(8):e29696. [7] LU J,GRENACHE D G.Development of an automated enzymatic method to quantify pyruvate kinase in red blood cells[J]. J Appl Lab Med,2020,5(1):54-61. [8] 沈悌,赵永强主编.血液病诊断及疗效标准[M].第4版.北京:北京科学出版社,2018:56-57. [9] 李津婴,万数栋主编.溶血性疾病[M].上海:复旦大学出版社,2008:303-316. [10] PALMER L,BRIGGS C,MCFADDEN S,et al.ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features[J]. Int J Lab Hematol,2015,37(3):287-303. [11] PARK S J,YOON J,KWON J A,et al.Evaluation of the CellaVision advanced RBC application for detecting red blood cell morphological abnormalities[J]. Ann Lab Med,2021,41(1):44-50. [12] MIWA S.Recommended methods for the characterization of red cell pyruvate kinase variants. International Committee for Standardization in Haematology[J]. Br J Haematol,1979,43(2):275-286. [13] LAAS C,LAMBERT C,SENIOR MCKENZIE T,et al.Improving the laboratory diagnosis of pyruvate kinase deficiency[J]. Br J Haematol,2021,193(5):994-1000. [14] 宋琳,李园,彭广新,等.先天性丙酮酸激酶缺乏症临床及实验室检查特征分析[J].中华内科杂志,2018,57(7):511-513. [15] GRACE R F,MARK LAYTON D,BARCELLINI W.How we manage patients with pyruvate kinase deficiency[J]. Br J Haematol,2019,184(5):721-734. [16] AL-SAMKARI H,VAN BEERS E J,MORTON D H,et al. Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency[J]. Blood Adv,2022,6(6):1844-1853. [17] CHONAT S,EBER S W,HOLZHAUER S,et al.Pyruvate kinase deficiency in children[J].Pediatr Blood Cancer,2021,68(9):e29148. [18] MENTZER W C,BAEHNER R L,SCHMIDT-SCHÖNBEIN H,et al. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency[J]. J Clin Invest,1971,50(3):688-699. [19] AL-SAMKARI H,ADDONIZIO K,GLADER B,et al.The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency[J]. Br J Haematol,2021,192(6):1092-1096. [20] JAMWAL M,AGGARWAL A,PALODHI A,et al.Next-generation sequencing-based diagnosis of unexplained inherited hemolytic anemias reveals wide genetic and phenotypic heterogeneity[J]. J Mol Diagn,2020,22(4):579-590. [21] AL-SAMKARI H,VAN BEERS E J,KUO K H M,et al. The variable manifestations of disease in pyruvate kinase deficiency and their management[J]. Haematologica,2020,105(9):2229-2239. |